Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate

MET, the cell-surface receptor for the hepatocyte growth factor/scatter factor, which is widely overexpressed in various solid cancer types, is an attractive target for the development of antibody-based therapeutics. BYON3521 is a novel site-specifically conjugated duocarmycin-based antibody–drug co...

Descripción completa

Detalles Bibliográficos
Autores principales: Groothuis, Patrick G., Jacobs, Daniëlle C.H., Hermens, Inge A.T., Damming, Désirée, Berentsen, Kim, Mattaar-Hepp, Ellen, Stokman, Marloes E.M., van Boekel, Tinie, Rouwette, Myrthe, van der Vleuten, Monique A.J., Sesink, Aloys, Dijcks, Fred A., Coumans, Ruud G.E., Schouten, Jan, Glaudemans, Dirk H., van Wijk, Daniëlle, Blomenröhr, Marion, Kappers, Wendela A., Ubink, Ruud, van der Lee, Miranda M.C., Dokter, Wim H.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233350/
https://www.ncbi.nlm.nih.gov/pubmed/37042205
http://dx.doi.org/10.1158/1535-7163.MCT-22-0596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233350/
https://www.ncbi.nlm.nih.gov/pubmed/37042205
http://dx.doi.org/10.1158/1535-7163.MCT-22-0596

Ejemplares similares